Gene · 3036
NIH grants1,858
NIH grants whose papers are about the gene, through NIH's grant-paper links.
141 to 160 of 1,858
Download this page as JSON| Grant | Title | HAS1 papers | Newest fiscal year |
|---|---|---|---|
| R01AI134886 | Mechanistic characterization and regulation of the non-redundant phu and has heme uptake systems of Pseudomonas aeruginosa | 1 | 2025 |
| R01AI146257 | Gut microbiome communication with the bone marrow regulates intestinal inflammation. | 1 | 2025 |
| R01AI152477 | Mechanisms of Fecal Microbiota Transplant Protection from Recurrent C. difficile | 1 | 2025 |
| R01AI155447 | Systemic coordination of pro-inflammatory immune reactions through dendritic cell-restricted sIL6R biogenesis | 1 | 2025 |
| R01AI155975 | Selecting HA glycosylation for improved vaccine responses | 1 | 2025 |
| R01AI165692 | Automated chemo-enzymatic synthesis of N-glycans for host-pathogen interactions | 1 | 2025 |
| R01AI168178 | Structural interrogation of vaccine- and infection-induced B cell responses | 1 | 2025 |
| R01AI169619 | Flipped Germinal Centers | 1 | 2025 |
| R01AI170715 | Antibody Durability Dynamics | 1 | 2025 |
| R01AI171445 | Genetic and biophysical mechanisms that control influenza virus cellular multiplicity of infection | 1 | 2025 |
| R01AR063709 | Expanded fibroblast subset drives pathology in rheumatoid arthritis | 1 | 2025 |
| R01AR063759 | Defining the influence of RA genetic susceptibility factors on T cell antigen specificity and functional state | 1 | 2025 |
| R01AR064327 | Reprogramming and Directed Differentiation of Skeletal Muscle Cells from hPSCs | 1 | 2025 |
| R01CA068682 | Biomedical Applications of Expanded Porphyrins | 1 | 2025 |
| R01CA080728 | Oncogenic Impact of eIF4E-dependent RNA Export in Cancer | 1 | 2025 |
| R01CA098571 | Molecular Mechanisms of eIF4E Mediated Transformation | 1 | 2025 |
| R01CA161112 | OVERCOMING STROMAL BARRIERS TO THERAPEUTICS IN PANCREAS CANCER | 1 | 2025 |
| R01CA182076 | Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas | 1 | 2025 |
| R01CA197296 | Targeting the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer with a Neoadjuvant Platform Clinical Trial | 1 | 2025 |
| R01CA240965 | The role of multi-cellular aggregates vs. individual tumor cells in metastasis of high-grade serous ovarian cancer | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/3036/grants?page=8